CAMP4 THERAPEUTICS CORP (CAMP)
US1281262089
Taking everything into account, CAMP scores 1 out of 10 in our fundamental rating. CAMP was compared to 568 industry peers in the Biotechnology industry. CAMP may be in some trouble as it scores bad on both profitability and health. CAMP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CAMP has reported negative net income.
CAMP had a positive operating cash flow in the past year.
In the past 5 years CAMP reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CAMP reported negative operating cash flow in multiple years.
1.2 Ratios
CAMP has a Return On Assets of -36.04%. This is in the better half of the industry: CAMP outperforms 61.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.04% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-9.56%
ROA(5y)-8.32%
ROE(3y)-107.81%
ROE(5y)-74.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CAMP has a better Gross Margin (35.78%) than 75.93% of its industry peers.
In the last couple of years the Gross Margin of CAMP has declined.
The Profit Margin and Operating Margin are not available for CAMP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.78%
GM growth 5Y-2.17%
2. Health
2.1 Basic Checks
CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAMP has been increased compared to 1 year ago.
The number of shares outstanding for CAMP has been increased compared to 5 years ago.
Compared to 1 year ago, CAMP has a worse debt to assets ratio.
2.2 Solvency
CAMP has an Altman-Z score of -0.03. This is a bad value and indicates that CAMP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CAMP (-0.03) is better than 63.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.03 |
ROIC/WACCN/A
WACC6.91%
2.3 Liquidity
CAMP has a Current Ratio of 1.69. This is a normal value and indicates that CAMP is financially healthy and should not expect problems in meeting its short term obligations.
CAMP has a Current ratio of 1.69. This is in the lower half of the industry: CAMP underperforms 79.65% of its industry peers.
CAMP has a Quick Ratio of 1.35. This is a normal value and indicates that CAMP is financially healthy and should not expect problems in meeting its short term obligations.
CAMP's Quick ratio of 1.35 is on the low side compared to the rest of the industry. CAMP is outperformed by 82.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The earnings per share for CAMP have decreased strongly by -17446.15% in the last year.
Measured over the past 5 years, CAMP shows a small growth in Earnings Per Share. The EPS has been growing by 1.49% on average per year.
The Revenue has decreased by -7.05% in the past year.
CAMP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.22% yearly.
EPS 1Y (TTM)-17446.15%
EPS 3Y42.01%
EPS 5Y1.49%
EPS Q2Q%-1647.16%
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y-2.86%
Revenue growth 5Y-4.22%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, CAMP will show a very negative growth in Earnings Per Share. The EPS will decrease by -57.66% on average per year.
Based on estimates for the next years, CAMP will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-592.19%
EPS Next 2Y-108.36%
EPS Next 3Y-57.66%
EPS Next 5YN/A
Revenue Next Year-92.93%
Revenue Next 2Y-46.85%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CAMP indicates a rather cheap valuation: CAMP is cheaper than 94.34% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 38.45 |
4.3 Compensation for Growth
A cheap valuation may be justified as CAMP's earnings are expected to decrease with -57.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-108.36%
EPS Next 3Y-57.66%
5. Dividend
5.1 Amount
CAMP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CAMP4 THERAPEUTICS CORP
NASDAQ:CAMP (12/18/2024, 3:34:03 PM)
5
-0.81 (-13.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap100.80M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.04% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.78% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-17446.15%
EPS 3Y42.01%
EPS 5Y
EPS Q2Q%
EPS Next Y-592.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y-2.86%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y